Food noise: what it is, and why GLP-1 medicines turn it down

What food noise is

For years, constant thinking about food was put down to a lack of willpower. In 2025, a group of researchers who study it proposed a formal definition: persistent thoughts about food that the person perceives as unwanted or distressing, and that may cause social, mental or physical harm. It describes a constant preoccupation with food decisions: what to eat, how much, when. The authors note it is being cited as one reason attempts to lose weight fail.

It can be measured. A five-item Food Noise Questionnaire was tested in 400 adults in 2025. It gave consistent results when people filled it in twice, a week apart, and its authors say more research is needed on how useful it is in clinics.

Not everyone thinks the concept is settled. A 2026 commentary in Appetite argues that food noise overlaps with older ideas such as cravings and food preoccupation, and needs sharper definition. The experience is real; the science of it is young. (See food noise coming back.)

What GLP-1 medicines do to it

• Semaglutide 2.4 mg. In a 20-week trial, people ate 35% less at a free-choice lunch than on placebo, and reported fewer and weaker food cravings and better control of eating.
• Semaglutide 1 mg. In a 12-week trial, people had less hunger, fewer food cravings, better control of eating and less preference for high-fat foods.
• Tirzepatide. In a 6-week trial, people reported less craving, less tendency to overeat, less hunger and less reaction to food around them than on placebo.
• In everyday use. A 2026 survey of 550 US adults taking semaglutide, whose authors included staff of its manufacturer, found the median Food Noise Questionnaire score fell from 13 out of 20 before treatment to 6. People were remembering how they felt before, so treat the size of the drop with care.

When researchers interviewed 30 people about their experience of these medicines in 2026, less food noise was one of the main themes. In another 2026 interview study, people still losing weight described reduced food noise and diminished cravings, and smaller portions persisted once their weight had stabilised.

Why it happens

GLP-1 is a hormone your gut releases after eating. As well as helping control blood sugar, it slows the emptying of the stomach and reduces food intake. The medicines act on the same receptor and last far longer.

Brain scanning studies suggest where some of that happens. In a 2014 study of 48 people, the GLP-1 medicine exenatide reduced how much people ate and dampened brain responses to food pictures in areas involved in appetite and reward, including the insula and amygdala. Blocking the GLP-1 receptor first largely stopped those effects. In the 2025 tirzepatide trial, brain responses to pictures of high-fat, high-sugar foods fell compared with placebo in several brain areas, including the orbitofrontal cortex.

So when the noise goes quiet, it is not that you suddenly found willpower. A signal that was always part of how appetite works has been made stronger.

When the quiet feels strange

For people who have lived with food noise for years, the relief can be large. It can also be unsettling. The 2025 joint advisory from four US nutrition and obesity medicine societies notes that frustration, or losing some of the pleasure food used to bring, can change mood for some people. A 2026 European consensus statement describes identity-related challenges during treatment, including shifts in food reward, coping and social connection, and recommends psychological screening, with support where needed.

The joint advisory also recommends screening for eating disorders, including binge eating disorder, before prescribing. If you find yourself restricting hard, bingeing, or feeling that food is out of control, tell your GP or prescriber. That is a reason for support, not a failure. (See GLP-1 medicines and anxiety.)

Using the quiet well

When food noise fades, so does the reminder to eat. The joint advisory notes that less interest in food can lead people to go several hours without eating, which can mean undernutrition for some. It also notes that rapid weight loss on these medicines frequently includes muscle as well as fat, and it makes enough protein a priority.

• Eat regularly, even when you are not hungry. The advisory suggests regular, small meals at consistent times rather than becoming overly hungry.
• Start meals with protein. (See protein on a GLP-1.)
• Keep up strength training to protect muscle. (See keeping muscle on a GLP-1.)
• If it is an empty stomach rather than chatter, that is a different problem. (See still hungry on Mounjaro or Wegovy.)

What to do with this

When food noise goes quiet, so does the reminder to eat. That is why this site leads with a floor rather than a limit: on a GLP-1, the more common risk is eating too little, not too much.

See your floor

Sources

1. Dhurandhar EJ, et al. Food noise: definition, measurement, and future research directions. Nutr Diabetes 2025. PubMed
2. Diktas HE, et al. Development and validation of the Food Noise Questionnaire. Obesity 2025. PubMed
3. Brewis A, et al. Food noise: Conceptual, methodological, and ethical considerations. Appetite 2026. PubMed
4. Friedrichsen M, et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab 2021. PubMed
5. Blundell J, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab 2017. PubMed
6. Martin CK, et al. Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial. Nat Med 2025. PubMed
7. Arnaut T, et al. Retrospective Assessment of Food Noise Changes After Initiation of Injectable Semaglutide for Weight Management in the USA: The INFORM Survey. Adv Ther 2026. PubMed
8. de Vere Hunt I, et al. Patient Experiences With GLP-1 Receptor Agonists. JAMA Netw Open 2026. PubMed
9. Chong MC, et al. Changes in Eating Behaviour During Treatment With Obesity Medications. Clin Obes 2026. PubMed
10. Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab 2018. PubMed
11. van Bloemendaal L, et al. GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans. Diabetes 2014. PubMed
12. Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory. Obesity Pillars 2025. PubMed
13. Dobbie LJ, et al. Nutritional, functional, and psychological considerations for incretin-based therapies in adults: an EASO, EFAD, and ECPO Consensus Statement. Lancet Diabetes Endocrinol 2026. PubMed
14. Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab 2022. PubMed

Medical disclaimer: Articles in the foodose research library are educational, not medical advice. If food, eating or body image is causing distress, speak with your doctor or a qualified professional. See our full medical disclaimer.